A fixed-dose combination drug containing an antibiotic—3rd generation cephalosporin ceftazidime and a novel non-β-lactam β-lactamase inhibitor avibactam.
Tradename Avycaz.
Routes of administration Intravenous infusion.
Used for the treatment of complicated intra-abdominal infections.
In complicated intra-abdominal infections it is used in the combination with metronidazole, which provides coverage for anaerobic pathogens.
It is also used for the treatment of complicated urinary tract infections, including acute pyelonephritis (AP), in adult patients.
Should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria to avoid development of antimicrobial resistance.
The antibacterial spectrum of ceftazidime/avibactam includes nearly all Enterobacteriaceae.
Activity against Pseudomonas aeruginosa is variable, due to the potential presence of other resistance mechanisms in addition to β-lactamase production.
It offers little or no advantage over ceftazidime monotherapy, again due to the widespread expression of resistance mechanisms other than β-lactamase production: include Haemophilus, Moraxella and Neisseria pathogens, and infections caused by Acinectobacter
Resistance to cephalosporins among gram-negative bacterial pathogens, especially among hospital-acquired infections, results in part from the production of β-lactamase enzymes that deactivate these antibiotics.
Most common adverse reactions are gastrointestinal disorders, blood alkaline phosphatase increase, alanine aminotransferase increase, dizziness and anxiety.